



## ASX Announcement

9 March 2021

### Formation of International Scientific Advisory Board

#### R&D Video Conference Planned for Investors

MELBOURNE, AUSTRALIA (9 March 2021): Hexima Limited (ASX:HXL) a clinical stage biotechnology company developing HXP124, a new prescription treatment for onychomycosis, today announces the formation and first meeting of its Scientific Advisory Board (SAB). Hexima will host an R&D video conference call for shareholders and investors at 11:00 AM (AEDT) on 25 March 2021 to share an overview of scientific data presented and discussed at its Scientific Advisory Board meeting (further details below).

Hexima has assembled a group of internationally recognised expert clinical opinion leaders comprising Dermatologists and Podiatrists based in US, Australia and Japan to act as its SAB. Members include the lead clinicians from advanced clinical trials conducted for multiple successful therapeutic products developed to treat onychomycosis in international markets. The board has held its inaugural meeting, discussing the scientific and early clinical data supporting the unique activity of Hexima's lead product, HXP124.

"We are pleased to have such a distinguished and accomplished group of clinical leaders as founding members of our Scientific Advisory Board" said Michael Aldridge, Managing Director & CEO of Hexima. Nicole van der Weerden, Chief Operating Officer and Executive Director added, "The SAB's experience, deep insight and guidance will be invaluable as we progress development of our lead pipeline candidate, HXP124, a potential new prescription treatment for toenail fungal infections (or onychomycosis)."

The SAB met virtually to discuss the scientific and early clinical data supporting HXP124. They reviewed:

- The distinctive ability of HXP124 to rapidly and effectively penetrate the human toenail and so reach the site of infection under the nail plate. Coupled with its powerful fungicidal activity and novel mechanism of action, this supports HXP124's therapeutic potential for this difficult to treat and very common disease.
- Hexima's completed clinical trial data which documents the potential of HXP124 to treat onychomycosis with a short course of treatment vs current prescription therapies. In a phase I/IIa study, following just 6 weeks of daily therapy, at the 12-week follow-up visit, the mycological cure rate was 52%, and clinical efficacy (<10% infected nail area) was 19.5% in the HXP124 treated groups.

Founding members of Hexima's Scientific Advisory Board comprise (complete Bios are over page):

- **Mark G. Lebwohl, MD** Mt. Sinai Hospital, New York, NY
- **Boni Elizabeth Elewski, MD** The University of Alabama at Birmingham, Birmingham, AL
- **Richard K. Scher, MD** Weill Cornell Medical Center, New York, NY
- **Warren Joseph, DPM** Roxborough Memorial Hospital, Philadelphia, PA



- **Tracey C. Vlahovic, DPM FFPM RCPS (Glasg)** Temple University School of Podiatric Medicine, Philadelphia, PA
- **Phoebe Rich, MD** Oregon Dermatology and Research Center, Portland, OR
- **Assoc. Prof. Peter Foley, MD** Skin Health Institute, Melbourne, Australia
- **Robert Rosen, MD** SouthDerm, Sydney, NSW
- **Prof. Shinichi Watanabe, MD, PhD** Department of Dermatology, Teikyo University School of Medicine, Tokyo

## **R&D Video Conference**

Hexima will host an R&D video conference call at 11:00 AM (AEDT) on 25 March 2021 to share an overview of scientific data presented and discussed at its Scientific Advisory Board meeting. Shareholders, investors and other interested parties are invited to register and attend via the following link. Further details on how to attend will be provided by email following registration.

<https://zoom.us/j/99985544882?pwd=WkN4SzJ3VE9CZ1FPQ2VOaTY2dG1qZz09>

## **Detailed Biographies: Hexima Scientific Advisory Board**

### **Mark G. Lebwohl, MD Mt. Sinai Hospital, New York, NY**

Dr Mark Lebwohl is Dean for Clinical Therapeutics and Chairman Emeritus of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai. He is a past President of the American Academy of Dermatology and Chairman Emeritus of the Medical Board of the National Psoriasis Foundation. He received his degree in medicine from Harvard Medical School in Boston, Massachusetts, USA, and completed his internship and residency in internal medicine, as well as his residency in dermatology at Mount Sinai Hospital in New York.

### **Boni Elizabeth Elewski, MD The University of Alabama at Birmingham, Birmingham, AL**

Dr Boni Elizabeth Elewski is Professor and Chair, Director of Clinical Research, and Residency Program Director at the University of Alabama at Birmingham, Department of Dermatology. Dr Elewski is a world-renowned expert dermatologist and educator. Dr. Elewski completed her medical degree at the Ohio State University, College of Medicine, Columbus, Ohio and her Internal Medicine and Dermatology residency at the University of North Carolina Memorial Hospital, Chapel Hill, North Carolina.

### **Richard K. Scher, MD Weill Cornell Medical Center, New York, NY**

Dr Richard Scher received his medical education at Howard University College of Medicine, and trained as a resident in dermatology at New York University. Dr Scher is a nail specialist and professor of Clinical Dermatology at Weill Cornell Medical College in New York City. Dr Scher is a leading expert in nail disorders, including fungal diseases and nail surgery, and is involved in clinical research and has established nail clinics at New York University, Brown University, Columbia University and University of North Carolina.

### **Warren Joseph, DPM Roxborough Memorial Hospital, Philadelphia, PA**

Dr Warren S. Joseph is a specialist in the treatment of lower extremity infectious diseases. He received his podiatric degree, magna cum laude, from W.M. Scholl College of Podiatric Medicine in Chicago. Dr Joseph completed his postgraduate training in podiatric medicine/surgery at St. Joseph's Hospital, and



a fellowship in infectious diseases at Hahnemann University School of Medicine, both in Philadelphia. He is currently an Adjunct Clinical Professor at the Arizona College of Podiatric Medicine at Midwestern University in Glendale, AZ.

**Tracey C. Vlahovic, DPM FFPM RCPS (Glasg) Temple University School of Podiatric Medicine, Philadelphia, PA**

Dr Tracey Vlahovic is a Clinical Professor and J. Stanley and Pearl Landau Faculty Fellow at the Temple University School of Podiatric Medicine (TUSPM) in Philadelphia, PA. She is also a member of the Faculty of Podiatric Medicine of the Royal College of Physicians and Surgeons (Glasgow). Dr Vlahovic graduated from Yale University with a BS in Molecular Biophysics and Biochemistry and received her medical degree from TUSPM. After finishing her surgical residency at St Luke's University Health Network in Allentown, PA, she was the first podiatrist in the US to complete a fellowship in podiatric dermatology under the supervision of Stephen Schleicher, MD.

**Phoebe Rich, MD Oregon Dermatology and Research Center, Portland, OR**

Dr Phoebe Rich is Adjunct Professor of Dermatology and director of the Nail Disorder Clinic at Oregon Health & Science University (OHSU). She has been in private practice in Portland for 30 years. She received her medical degree and performed her Dermatology residency at OHSU. She is a member of the Council of Nail Disorders, European Nail Society, and has served on the Board of Directors of the American Academy of Dermatology. Dr Rich lectures nationally and internationally on the importance of inflammatory, neoplastic, and infectious nail conditions. She has been involved as principal investigator in over 400 clinical trials and has authored numerous chapters and over 80 publications in peer-reviewed journals.

**Peter Foley MBBS, MD, FACD Skin Health Institute, Melbourne, Australia**

Associate Professor Peter Foley graduated MBBS, BMedSc from Monash University in 1987, and MD from The University of Melbourne in 1996. He completed his dermatology training in Melbourne, obtaining Fellowship of the Australasian College of Dermatologists in 1997. He is Director of Research at the Skin Health Institute and the Head of Dermatology Research at St Vincent's Hospital Melbourne. He currently holds the position of Associate Professor, Department of Medicine at The University of Melbourne. In addition to running a busy private practice, he is a visiting medical officer to the Photobiology, Dermatology Biologics, and Dermatology Investigation clinics at St Vincent's Hospital Melbourne, and the Phototherapy and Biologics clinics at the Skin Health Institute.

**Robert Rosen, MD SouthDerm, Sydney, NSW**

Dr Robert Rosen obtained his medical degree from the University of New South Wales and completed additional training at Stanford University, USA. Dr Rosen completed his dermatology specialist training at the Skin and Cancer Foundation Australia and St Vincent's and Prince of Wales hospitals, NSW, and obtained a Master of Medicine degree from the University of Sydney. Dr Robert Rosen obtained his medical degree from the University of New South Wales and completed additional training at Stanford University, USA. Dr Rosen completed his dermatology specialist training at the Skin and Cancer Foundation Australia and St Vincent's and Prince of Wales hospitals, NSW, and obtained a Master of Medicine degree from the University of Sydney.

**Shinichi Watanabe, MD, PhD Department of Dermatology, Teikyo University School of Medicine, Tokyo** Professor Shinichi Watanabe is Professor Emeritus of the Department of Dermatology, Teikyo University School of Medicine and is also specially appointed Professor of Teikyo University Institute of



Medical Mycology. He obtained his medical and PhD degrees from the University of Tokyo and his research fellowship from the Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

All members of Hexima's Scientific Advisory Board receive financial compensation from Hexima for the provision of consulting services.

#### **About Hexima**

Hexima (ASX:HXL) is an anti-infectives focused, clinical stage, biotechnology company engaged in the research and development of plant-derived defensin peptides for applications as human therapeutics. Its lead product candidate, HXP124 applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial of HXP124 in onychomycosis. Hexima holds granted, long-life patents protecting HXP124 and other anti-fungal molecules in major markets globally. For additional information about Hexima please visit [www.hexima.com.au](http://www.hexima.com.au).

**This announcement is authorised for release to ASX by Michael Aldridge, Managing Director & CEO**

#### ***Enquiries:***

Dr Nicole van der Weerden  
Chief Operating Officer  
[n.vanderweerden@hexima.com.au](mailto:n.vanderweerden@hexima.com.au)

#### ***Join our email database to receive company announcements:***

[Info@hexima.com.au](mailto:Info@hexima.com.au)  
[www.hexima.com.au](http://www.hexima.com.au)